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ABSTRACT 
Objective: Pulsatile systems are gaining a lot of significance as they deliver the drug at the right site of action at the right time and in the right 
amount, thus providing spatial and temporal delivery and increasing patient compliance. These systems are designed according to the circadian 
rhythm of the body. The aim of the present research work was to design and optimize compression coated floating pulsatile drug delivery system of 
Famotidine. Floating pulsatile concept was applied to increase the gastric residence of the dosage form having lag phase followed by a burst release. 
Methods: Floating pulsatile tablets were prepared by using press coated technology. The prepared system consisted of two parts: a core tablet 
containing the active ingredient and an erodible outer shell with gas generating agent. The burst release core tablet was prepared by using super 
disintegrants with the active ingredient. Press coating of optimized burst release core tablets was done by the polymer. A 32 full factorial design was 
used for optimization. The amount of HPMCE4M and Polyox WSRN60K was selected as independent variables. Lag period, drug release, buoyancy 
and swelling index were selected as dependent variables.  
Results: Floating pulsatile release formulation (FPRF) F4 at level 0 (65 mg) for HPMC E4M and level-1 (75 mg) for Polyox WSR N60K showed lag 
time of 4 h with>90% drug release. The data were statistically analyzed using ANOVA, and 𝑃𝑃<0.05 was statistically significant.  
Conclusion: The present research work demonstrates that famotidine could be successfully delivered to provide night-time relief of gastric acidity 
by formulating floating pulsatile drug delivery system. The press-coated formulation containing HPMCE4M and Polyox WSR N60K at 0,-1 level was 
in the optimum zone and has the potential for time-controlled pulsatile delivery of Famotidine. 
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INTRODUCTION 
Amongst the various routes of drug delivery, oral route is perhaps 
the most preferred to the patient and the clinician alike. In oral 
route, time and site specific modified release dosage forms are 
gaining interest as they are programmed release dosage forms or 
pulsatile release dosage forms [1, 2]. Recent studies reveal that the 
body’s biological rhythm may affect normal physiological function, 
including gastrointestinal motility, gastric acid secretion, 
gastrointestinal blood flow, renal blood flow, hepatic blood flow, 
urinary pH, cardiac output, drug-protein binding, and liver 
enzymatic activity, and biological functions such as heart rate, blood 
pressure, body temperature, blood plasma concentration, 
intraocular pressure, stroke volume, and platelet aggregation [3]. 
Most organ functions vary with the time of the day, particularly 
when there are rhythmic and temporal patterns in the manifestation 
of a given disease state. The symptoms of many diseases, such as 
bronchial asthma, myocardial infarction, angina pectoris, 
hypertension, ulcers and rheumatic disease have followed the body’s 
biological rhythm [4-6]. 
Pulsatile drug delivery system is attaining the highest interest in the 
field of pharmaceuticals, as this drug delivery system is helping in 
rapid release of drug at the particular site after a pre-determined 
off-release period (lag time) matching with circadian rhythm and 
support for patient compliance [7, 8]. The time controlled function of 
third generation DDSs currently under development is finding 
application in new and improved disease therapeutics. Biological 
rhythms may be applied to pharmacotherapy by adopting a dosage 
form that synchronizes drug concentrations to rhythms in disease 
activity [9, 13]. 
Conventional pulsatile release dosage forms release the drug after 5-
6 h of lag period in lower part of gastrointestinal tract which is 
unfavourable for certain drugs which will degrade in higher pH 
conditions, which are undergo enzymatic degradation, which all 
leads to develop a gastro retentive drug delivery system which 
favours for retaining the drug at upper part of gastrointestinal tract, 
which won’t affected by change in pH, gastric emptying rate. This 
technology also favours for the drugs which have absorption 
window at stomach [14-17]. These considerations led to the 
development of pulsatile release dosage forms possessing gastric 
retention capabilities. Of the numerous approaches to prolong 
gastric retention, floating drug delivery system is the most widely 
used technique and offers a simple, practical approach to increased 
gastric residence through inherent buoyancy. 
Normal gastric acid secretion follows a circadian rhythm with a 
sudden surge of gastric acidity when the gastric pH level goes far 
below 4 for at least 1 h in the midnight. This pathophysiological 
condition is termed as a nocturnal acid breakthrough (NAB) and is 
even more prolonged and clinically critical for H. pylori-negative 
patients on proton pump inhibitor (PPI) therapy. It is demonstrated 
that adding a bed-time dose of H2 antagonist to an evening dose of 
proton pump inhibitor provides nocturnal recovery of gastric acid 
secretion. This limitation, however, can be overcome by a chrono 
therapeutic approach which will ensure that the highest blood levels 
of the drug coincide with the peak symptoms in early morning 
hours. Hence, a bedtime dosing of H2 antagonist from a pulsatile 
delivery system combined with normal twice a day PPI dosing would 
be a promising therapeutic regimen. 
Famotidine is histamine H2-receptor antagonist used for duodenal 
ulcer, benign gastric ulcer, gastro-oesophageal reflux disease 
(GERD), and nocturnal acid breakthrough with half-life 2.5-3.5 h [18-
22]. Polyox are water soluble resins. Polyox WSRN60K, HPMCE4M 
are highly water soluble polymers. Upon exposure to water or 
gastric juice, they hydrate and swell rapidly to form hydrogels with 
properties suited for controlled drug delivery. The current research 
work shows the development of specific technology, based on 
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combining floating and pulsatile principles. Floating pulsatile drug 
delivery system of famotidine was prepared by compression coating 
technology utilising design of experiments for optimization. 
MATERIALS AND METHODS 
Materials 
Famotidine was generously gifted by Dr. Reddy’s Lab. Hyderabad. 
HPMC E4M and Polyethylene Oxide (Polyox WSRN60K) were gifted 
by Colorcon Asia Pvt. Ltd., Goa, India. Croscarmellose sodium, 
Crospovidone, Sodium starch glycolate and microcrystalline 
cellulose were gifted by Dr. Reddy’s Lab. Hyderabad, India. 
Methods 
Drug-excipient interaction 
To investigate the chemical interaction, Fourier transformed 
infrared (FTIR) analysis of famotidine and the chosen excipients 
used in the formulation were carried out over the range of 400-4000 
cm-1 using FTIR spectrometer (Bruker, Alpha-T, Ettlingen, Germany). 
The spectra obtained for pure drug alone and in combination with 
excipients were compared to confirm the interaction.  
Preparation of burst releases core tablets 
The core tablets were prepared by direct compression method. 
Required quantities of Famotidine, microcrystalline cellulose (MCC, 
Avicel PH-102) and super disintegrant were dispensed and sieved 
through #40 mesh and dry blended in a polybag for 10 min. The 
blend was lubricated for 5 min in a polybag with the addition of 
magnesium stearate. Different types of super disintegrants with 
concentrations of 5% and 10 % were used in the formulations. Then 
lubricated blend compressed into round-shaped tablets with table 
top pilot scale 10 stations rotary rimek mini press-I using 6 mm 
round punch (M/S Karnavati Engineering Ltd., Gujarat, India). Table 
1 summarizes the composition of burst release core tablets. 
 
Table 1: Composition details of core tablets 
Ingredients C1 C2 C3 C4 C5 C6 
Famotidine (mg) 40 40 40 40 40 40 
Croscarmellose sodium(mg) 3.75 7.5 - - - - 
Crospovidone(mg) - - 3.75 7.5 - - 
Sodium starch glycolate(mg) - - - - 3.75 7.5 
Magnesium stearate(mg) 3 3 3 3 3 3 
Microcrystalline cellulose (mg) 28.25 24.5 28.25 24.5 28.25 24.5 
Total tablet weight (mg) 75 75 75 75 75 75 
 
Formulation of floating pulsatile release tablets with individual 
polymers 
Press coated technology [23] was used for preparing floating 
pulsatile drug release tablets using HPMC E4M, Polyox WSR N60K 
polymers, sodium bicarbonate, and citric acid as a gas generating 
agent in batch A1 to A7. Initial screening trials were taken to 
optimise the concentration of sodium bicarbonate. The concentration 
of gas generating agent was varied between 15% (56 mg) to 25% 
(95%) of sodium bicarbonate, the concentration of citric acid was fixed 
as 30 mg. After finalizing the optimum concentration of gas generating 
agents, the concentration of individual polymer was determined and 
used in designing the experiment of factorial design.  
Press-coated tablets were prepared by keeping 50% barrier layer 
material into a 9 mm die; then the core tablet was placed at the 
centre. The remaining half of the barrier layer material was added 
into the die and compressed. Table 2 summarizes the composition of 
the floating pulsatile release tablet (FPRT) trial batches with 
individual polymers. 
 
Table 2: Composition of the floating pulsatile release tablet (FPRT) trial batches with individual polymers 
Ingredients A1 A2 A3 A4 A5 A6 A7 
Core tablet (mg) 75 75 75 75 75 75 75 
HPMC E4M(mg) 75 75 75 140 180 - - 
Polyox-N60K(mg) 75 75 75 - - 130 170 
Sodium bicarbonate(mg) 56 75 95 75 75 75 75 
Citric acid(mg) 30 30 30 30 30 30 30 
Microcrystalline cellulose (mg) 64 45 25 55 15 45 25 
 
Formulation of the floating-pulsatile release tablets (FPRT) 
using experimental design 
A full factorial32 design was used for optimization procedure. It 
is suitable for investigating the quadratic response surfaces and 
for constructing a second order polynomial model, thus enabling 
optimization of the time-lagged coating process. Mathematical 
modeling, evaluation of the ability to fit to the model and 
response surface modeling were performed with employing 
Design-Expert. A 32 randomized reduced factorial design was 
used in this study, and 2 factors were evaluated, each at 3 levels; 
experimental trials were performed at all 9 possible 
combinations prepared according to the formula. table 3 
summarizes the independent and dependent variables along 
with their levels. The resulted formulations (testing runs) are 
listed in table 4. 
  
Table 3: Variables and constraints in full factorial experimental design 
Independent variable Level Constrains 
-1 0 1 
X1: HPMC E4M (mg)  55 65 75 In range 
X2: Polyox WSR N60K (mg) 75 85 95 In range 
Dependent variables 
Y1: Swelling Index  
Y2: Buoyancy lag time (Sec) 
Y3: Cumulative drug release at 4th h (%) 
Y4: Cumulative drug release at 6th h (%) 
Y5: Lag period (H) 
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Table 4: Observed responses in full factorial design for famotidine floating pulsatile tablets 
Formula code Independent variables Dependent variables 
X1 X2 Swelling index (%) Buoyancy lag time (Sec) YQ4 YQ6 Lag period (H.) 
F1` -1 -1 122.11 112 97.02 99.89 2 
F2 -1 0 127.4 113 97.1 99.56 3 
F3 -1 +1 129 116 90.69 99.47 3 
F4 0 -1 140 101 93.1 99.96 4 
F5 0 0 156 118 3.48 89.27 5 
F6 0 +1 167.4 113 3.87 80.94 6 
F7 +1 -1 176.3 115 2.94 75.61 7 
F8 +1 0 189.8 112 3.87 66.96 8 
F9 +1 +1 206.1 120 5.35 59.94 8 
Coded values Actual values 
X1 (mg) X2 (%) 
-1 55 75 
0 65 85 
1 75 95 
X1–Amount of HPMC E4M; X2-amount of Polyox WSR N60K; YQ4-% Cumulative drug release at 4th h; YQ6-% Cumulative drug release at 6th h. In all the 
formulations, 75 mg of Sodium bicarbonate and 30 mg of citric acid was used. Final tablet weight was made up to 375 mg with microcrystalline 
cellulose 
 
The percentage of HPMC E4M (X1) and Polyox WSR N60K (X2) were 
selected as independent variables. Initial screening studies provided 
a setting of the levels for each formulation variables. Lag period of 4 
h, % drugs released at 4th hour and 6th hour, buoyancy and swelling 
index were selected as dependent variables. The batches were 
prepared as per the runs and evaluated the effect of individual 
variables on dependent variables according to response surface 
methodology 
𝑌𝑌 = bO+𝑃𝑃1𝑋𝑋1+𝑃𝑃2𝑋𝑋2+𝑃𝑃12𝑋𝑋1𝑋𝑋2+𝑃𝑃11𝑋𝑋21+𝑃𝑃22𝑋𝑋22---------------- (1) 
where 𝑌𝑌 is the dependent variable, bO is the arithmetic mean 
response of the 9 runs, and bi (𝑃𝑃1, 𝑃𝑃2, 𝑃𝑃12, 𝑃𝑃11, and 𝑃𝑃22) is the 
estimated coefficient for the corresponding factor Xi (𝑋𝑋1, 𝑋𝑋2, 𝑋𝑋1𝑋𝑋2, 
𝑋𝑋12, and 𝑋𝑋22), which represents the average result of changing 1 
factor at a time from its low to high value. The interaction term 𝑋𝑋1𝑋𝑋2) 
shows how the response changes when 2 factors are simultaneously 
changed. The polynomial terms (𝑋𝑋21 and 𝑋𝑋22) are included to 
investigate nonlinearity. 
Formulation of batches containing HPMC E4M and polyox WSR 
N60K as variables  
The batches containing HPMC E4M and Polyox WSR N60K were 
prepared according to the factorial design. The concentration of 
sodium bicarbonate and citric acid were kept constant at the 
optimum level. The optimum level was finalised on the basis of the 
results of the evaluation of initial screening trials. In this factorial 
design, the concentration of HPMC E4M and the concentration of 
Polyox WSR N60K were varied keeping the values of other 
ingredients constant. The minimum and maximum levels of the 
variables were decided on the basis of the predicted individual 
batches. The concentration of both polymers was finalized in the 
range of 35 to 45%, so as to study the combined effect of HPMC E4M 
and Polyox WSR N60K on the lag period, release pattern, and 
swelling index. Tablet batches contain HPMC E4M and Polyox N60K 
as the variables (F1–F9) according to the factorial design. The effect 
of the variables on the response was also studied by using the 
response surface methodology and statistical study by analysis of 
variance (ANOVA) which was studied by using the Design Expert® 
Software (Version 8.0.7.1, StatEase Inc., Minneapolis). The 
mathematical modeling and mathematical relationships generated 
using multiple linear regressions for the studied response variables 
are expressed in the form of equations. 
Manufacturing of compression coated tablets 
Floating pulsatile release tablets were prepared as per below 
procedure. HPMC E4M, Polyox WSR N60K, gas generating agent 
sodium bicarbonate, and citric acid were weighed and passed 
through sieve number 40 separately. Powder mixing was carried out 
using polyethene bag for 15 min. mixing was continued for another, 
10 min, and burst core release tablets were prepared according to 
the formula given in table-1. Press-coated tablets were prepared by 
keeping 50% barrier layer material into a 9 mm die; then the core 
tablet was placed at the centre. The remaining half of the barrier 
layer material was added into the die and compressed.  
Evaluation of floating-pulsatile release tablets (FPRT) 
Evaluation tests  
The evaluation was performed to assess the physicochemical 
properties of powder mixture and developed formulations and also 
their release characteristics.  
Physical properties of powder mixture 
Angle of repose 
It is the maximum angle that can be obtained between the free 
standing surface of a powder heap and the horizontal. Accurately 
weighed the quantity of powder is poured in the funnel and the 
height of funnel is adjusted to a height of 2.5 cm and the radius of the 
circle is measured by taking the diameter values of the average of 
four values and the half of the diameter is the radius. It can be 
calculated by using the formula, 
θ = tan-1 (h/r) 
Where, h = Height of the funnel 
r =Radius of circle 
Compressibility index 
Tapped density and bulk density were measured, and the 
compressibility index was calculated by the using the formula,  
% Compressibility index = [(ρt-ρo)/ρt] X100 
Where ρt = Tapped density 
ρo = Bulk density. 
Hausner’s ratio 
Tapped density and bulk density were measured, and the Hausner’s 
ratio was calculated by using the formula, 
Hausner’s ratio = ρt/ρo 
Where, ρt = Tapped density 
ρo = Bulk density. 
Physical characterization of the designed tablet 
The properties of the compressed matrix tablets, such as hardness, 
friability, weight variation and content uniformity were determined 
using reported procedure. 
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Hardness 
The hardness of tablet is defined as the force applied across the 
diameter of the tablet in order to break the tablet. The resistance of 
the tablet to chipping, abrasion or breakage under the condition of 
storage transformation and handling before usage depends on its 
hardness. Tablet hardness was determined for 10 tablets using a 
Monsanto tablet hardness tester.  
Friability 
Friability was determined by testing 10 tablets in a Roche friability 
tester. Accurately weighed ten tablets were placed in Roche 
Friabilator and rotated at 25 rpm for 4 min. The tablets were then 
de-dusted and re-weighed to determine the loss in weight. Friability 
was then calculated as percent weight loss from the original tablets. 
Percentage friability was calculated using the following equation. 
Friability = ([WO–W]/WO) × 100 
Where; WO = weight of the tablet at time zero before the revolution. 
W = weight of the tablet after revolutions at 4 min. 
Weight variation 
The weight variation was determined by taking the weight of 20 
tablets using an electronic balance (Electronic Balance). The average 
weight of all tablets was calculated. It passes the test for weight 
variation, if not more than two of the individual tablet weights 
deviate from the average weight by more than the allowed 
percentage deviation and none deviate by more than twice the 
percentage shown. 
Determination of % drug content 
The tablets were crushed in the mortar, and the powder equivalent 
to 20 mg of drug was dissolved in distilled water. The stock solutions 
were filtered through a membrane filter (0.45 mm). The solutions 
were then diluted suitably in 0.1N HCl. The drug content was 
analyzed at 266 nm by UV spectrophotometer (LABINDIA UV3200). 
Each sample was analyzed in triplicate. 
Swelling index determination 
Tablets were weighed individually (designated as 𝑊𝑊1) and placed 
separately in glass beaker containing 200 ml of 0.1NHCl and 
incubated at 37 °C±1 °C. At regular 1-h time intervals until 24 h, the 
tablets were removed from beaker, and the excess surface liquid was 
removed carefully using the paper. The swollen tablets were then 
reweighed (𝑊𝑊2) and swelling index (SI) was calculated using the 
following formula:  
SI =𝑊𝑊2−𝑊𝑊1/𝑊𝑊1 × 100 
Where 𝑊𝑊1= Initial weight; 𝑊𝑊2= Swollen tablet weight  
In vitro buoyancy determination 
Floating behaviour of the tablet was determined by using USP 
dissolution apparatus-II in 900 ml of 0.1NHCl which is maintained at 
37±0.5 °C, rotated at 50rpm. The floating lag time as well as total 
floating time is observed. 
In vitro dissolution studies 
In vitro release of Famotidine from the prepared Matrix tablets was 
studied using USP XXIV dissolution rate test apparatus-II (Model: 
LAB INDIA UV3200) employing the paddle stirrer. 900 ml of 0.1N 
HCl was used as dissolution medium maintained at a temperature of 
37±0.5 °C and the paddle was rotated at 50 rpm and is carried for 10 
h. At each interval of 1 hour, 5 ml of samples were withdrawn by 
means of a syringe fitted with a prefilter and immediately replaced 
with 5 ml of fresh medium. The absorbance of the samples was 
measured at 266 nm after suitable dilution with the medium using 
UV Spectrophotometer, and the results are as follows. 
Lag time 
Lag time was considered as the time when the tablet burst and core 
tablet is out of press coating. This is considered as predetermined 
off-release period. 
Stability testing of the best formulation 
A short-term stability study on optimized FPRT was carried out by 
storing the tablets at 25 °C (±2 °C) and 60% RH (±5%) and 40 °C (±2 
°C) and 75% RH (±5%) over a 3 mo period according to ICH 
guidelines. At the end of three months’ time interval, the tablets 
were examined for drug content, and floating duration. 
RESULTS AND DISCUSSION 
Evaluation of burst releases tablets 
The rapid increase in the disintegration of Famotidine with 
crospovidone at a concentration (5%) may be attributed to rapid 
swelling of the tablet. It was observed that disintegration time of 
tablet varies with different super disintegrants and at different 
concentration levels. Formulation C3 (5% crospovidone) showed 
lowest disintegration time (64 sec) with high drug release (99.8%). 
The results were captured in table 5, table 6 and fig. 1. For the 
development of pulsatile delivery, disintegration time must be short 
to obtain burst effect. The hardness was observed in the range of 
(2.4–2.7±0.18 Kg/cm2), whereas friability was less than 1% which 
indicated that tablet had good mechanical resistance. Drug content 
was found to be high (>98.14%) and uniform in all tablet 
formulations. C3 was taken as core tablet for pulsatile release tablet, 
and it was taken for further studies. 
 
Table 5: Physical properties of powder mixtures of burst release formulations 
Formulation code Angle of repose ( °) Compressibility index (%) Hausner's ratio 
C1 24.38±1.52 8.51±0.71 1.10±0.04 
C2 29.20±1.86 9.61±1.19 1.09±0.09 
C3 21.64±1.47 12.67±0.58 1.13±0.01 
C4 21.80±1.19 15.02±0.81 1.14±0.08 
C5 22.84±1.64 15.02±0.81 1.14±0.08 
C6 27.35±1.32 14.92±1.12 1.17±0.03 
Where n =3. Each value is mean±SD 
 
Table 6: Evaluation parameters of burst release tablets 
Formulation code Disintegration time (sec) Wetting time(sec) % drug content 
C1 78±0.57 98±0.84 98.43±0.54 
C2 72±0.52 96±0.97 98.89±0.76 
C3 64±0.51 84±0.86 99.52±0.58 
C4 73±0.58 98±0.92 98.46±0.56 
C5 69±0.62 90±0.94 99.36±0.62 
C6 75±0.59 97±0.82 98.14±0.56 
Where n =3. Each value is mean±SD 
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Fig. 1: In vitro drug release profile of core tablets. All values are represented as mean±SD (n=6) 
 
Evaluation of batches with individual polymers 
Drug release from the formulation was changed as the concentration 
of gas generating agent; NaHCO3 was changed. The increase in 
concentration of sodium bicarbonate affects the release pattern; 
buoyancy lag time and hardness of the formulation. The 
concentration of gas generating agent, sodium bicarbonate was 
varied between 15% (56 mg) to 25% (95 mg) and 30 mg citric acid 
to achieve optimum floating without affecting the release pattern of 
the drug from formulation and to obtain proper lag period. The 
optimum gas generating agent concentration was 20% (75 mg) for 
sodium bicarbonate and 8% (30 mg) citric acid.  
During the dissolution kinetics, the coating layer gradually starts to 
erode up to a limiting thickness of the coat. After this stage, a 
rupture of the shell was observed under the pressure which has 
applied by the swelling of the core tablet due to the presence of 
super disintegrant. This pressure was high due to the high swelling 
property of crospovidone, resulted in burst effect after 4 h along 
with complete and rapid drug release.  
In formulations, A3 and A6 amount of coating polymer was too less 
which could not maintain the integrity of tablet for long and time is 
resulting in complete drug release within a short period of time. 
Individual polymer batches (A4 and A6) containing HPMC E4M and 
Polyox WSR N60K in the concentration of 37% and 34% 
respectively, show burst effect after 3 h after that constant drug 
release over the period of 6 h. 
In batches A5 and A7 the amount of coating polymer was too high to 
achieve high lag time with minimum drug release. Individual 
polymer batches (A5 and A7) containing HPMC E4M and Polyox 
WSR N60K in the concentration of 48% and 45% respectively, show 
burst effect after 7 h. The drug release clearly depended on the kind 
and amount of hydrophilic polymers as that which was applied on 
the core. Hence, combination of these two polymers was used to get 
optimum floating ability and drug release. A formulation containing 
HPMC E4M (75 mg) and Polyox WSR N60K (75 mg) in combination 
showed optimum floating and released pattern. Hence this 
combination of polymers used for optimization study. 
Evaluation parameters of batches with individual polymers showed 
in table-7. Tablet weight variation varied between 374±1.3 mg to 
376±0.9 mg, the hardness of tablet varied between 6.1±0.57 kg/cm2 
to 8.9±0.68 kg/cm2, drug content; buoyancy and lag time of different 
formulation was varied between 98.14±0.57% to 99.52±0.74%; 
76±0.42 sec to 129±0.63 sec and 3 h to 7 h respectively. 
  
Table 7: Evaluation parameters of batches with individual polymers 
Trial batch 
code 
Weight variation (mg) (n 
=10) 
Hardness 
(Kg/cm2) 
(n =3) 
% Drug 
content 
(n =3) 
Buoyancy lag time (sec) (n 
=3) 
Lag period 
(Hr) 
A1 375±1.5 6.1±0.57 98.43±0.52 129±0.63 3 
A2 374±1.3 7.4±0.58 98.89±0.68 92±0.86 4 
A3 375±1.9 8.9±0.68 99.52±0.74 76±0.42 5 
A4 376±0.9 7.1±0.63 98.46±0.57 99±0.56 3 
A5 375±1.4 7.9±0.57 99.36±1.00 102±0.68 7 
A6 375±1.3  7.2±1.00 98.14±0.57 100±0.76 3 
A7 374±1.3  7.6±1.01 99.23±0.49 109±0.28 7 
Each value is mean±SD 
 
Table 8: Physical properties of powder mixtures of floating-pulsatile release tablets 
Formulation code Angle of repose ( °) Compressibility index (%) Hausner's ratio 
F1 26.36±1.73 11.71±1.56 1.17±0.01  
F2 24.38±1.52 10.71±0.84 1.13±0.02 
F3 29.20±1.86 11.98±1.58 1.12±0.03 
F4 21.64±1.47 8.51±0.71 1.10±0.04 
F5 21.80±1.19 9.61±1.19 1.09±0.09 
F6 21.80±1.19 12.67±0.58 1.13±0.01 
F7 22.84±1.64 15.02±0.81 1.14±0.08 
F8 27.35±1.32 14.92±1.12 1.17±0.03 
F9 28.64±1.58 16.59±0.97 1.19±0.04 
Where n=3, each value is mean±SD 
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Table 9: Evaluation of floating-pulsatile release tablets (F1–F9) 
F. Code Tablet weight (mg) % Drug content 
(n =10) 
Hardness 
(kg/cm2) 
Swelling index 
(%) 
Buoyancy lag time (sec) %drug release 
(n =3) 
F1 375±2.0 98.45±0.50 5±1.00 122.1±0.94 112±1.3 98.45±1.40 
F2 376±2.4 97.27±1.00 7±1.40 127.4±0.67 113±1.7 98.92±1.30 
F3 375±2.7 98.17±0.84 6±0.94 129.0±0.89 116±1.4 94.42±0.67 
F4 375±1.0 97.96±0.50 8±0.84 140.0±0.57 101±1.0 99.00±0.48 
F5 372±1.7 98.62±1.00 7±0.67 156.0±0.94 118±1.4 97.69±0.52 
F6 374±1.3 97.39±0.67 7±0.43 167.4±0.74 113±1.7 92.00±1.40 
F7 373±2.4 97.19±0.45 8±0.45 189.8±0.86 115±1.3 98.46±1.00 
F8 375±1.5 98.82±0.84 7±0.54 190.4±0.57 112±1.0 91.00±0.68 
F9 374±1.4 96.98±1.00 9±0.57 206.1±0.43 120±0.8 90.00±0.57 
Each value is mean±SD 
 
Evaluation of formulations with combination of polymers  
Most of the formulation blends showing good flow properties (table 
8). Physical parameters of different floating pulsatile release 
formulations were evaluated and depicted in table 9. Tablet weight 
variation varied between 372±1.7 mg to 376±2.4 mg, the hardness 
of tablet varied between 5.0±1.00 kg/cm2 to 9.0±0.57 kg/cm2, drug 
content; buoyancy and swelling index of the different formulation 
were varied between 96.98±1.00% to 98.82±0.84%; 101±1.0 sec to 
120±0.8 sec and 122.1±0.94% to 206.1±0.43% respectively. 
Swelling index 
The swelling index plays an important role in determining the 
retention ability of the tablets in the stomach. In formulations, F1–F9 
swelling index was in the range of 122.1±0.94% to 206.1±0.43%. In 
these formulations, maximum swelling index (206.1±0.43%) has 
been shown by F9 whereas minimum swelling index (122.1±0.94%) 
by F1. The effect of the variables on the swelling index and buoyancy 
in formulations F1–F9 are shown in below fig. 2 and fig. 3 
respectively:  
Swelling index =+157.12+32.28𝐴𝐴+10.68𝐵𝐵+5.73𝐴𝐴𝐵𝐵----------------- (2) 
All the polynomial equations were found to be statistically 
significant (𝑃𝑃<0.01), as determined using ANOVA, as per the 
provision of Design Expert software. The combined effect of 
concentration of HPMC E4M and Polyox WSR N60K on swelling 
index was shown in Pareto chart and contour plots. From response 
surface plot and contour plot, it was observed that there is a positive 
impact of polymers on selling index. From the Pareto chat it can be 
concluded that selling index majorly governed by HPMCE4M 
compared to Polyox WSR N60K. As there is an increase in the 
concentration of HPMC E4M and Polyox WSR N60K up to 
intermediate concentration (level 0) there is increase in swelling 
index [24]. 
 
 
 
 
Malladi et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 5, 169-181 
 
175 
  
 
Fig. 2: (a) Half-normal plot showing the influence on swelling Index, (b) Pareto chart, (c) Response surface plot, and (d) Contour plot 
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Fig. 3: (a) Half-normal plot showing the influence on buoyancy, (b) Pareto chart, (c) Response surface plot, and (d) Contour plot 
 
Lag period 
Lag period plays an important role in determining no or less amount 
drug releases of the tablets at a specific period. Nocturnal acid 
breakthrough typically appears in the second 6-hour period (2 to 4 
am), after the evening dose of a PPI when patients are sleeping. The 
half-life of Famotidine is 2.5 to 3.5 hr. However for such cases, 
conventional drug delivery systems are inappropriate for the 
delivery of Famotidine, as they cannot be administered just before 
the symptoms are worsened, because during this time the patients 
are asleep. To follow this principle, it was necessary to design the 
dosage form so that it can be given at the bed time giving drug 
release in the morning. Using current release technology, it was 
possible to get the rapid and transient release of a certain amount of 
drugs within a short time period immediately after a predetermined 
off-release period, that is, lag time. Famotidine, which has a local 
activity for acidity in the stomach and better bioavailability showing, 
as compared with lower parts of GIT. Overall, these considerations 
led to the development of oral pulsatile release dosage forms 
possessing gastric retention capabilities. In designing floating-
pulsatile system for Famotidine with a four-to-five-hour delay in a 
release after oral administration was considered as ideal. The dose 
administered at bedtime will give drug release in the early morning 
hours when the patient is most at risk. 
In the formulations from F1 to F9 lag period was in the range of 2–
8±0.2 h. In this set of formulation, optimum lag period (4.2±0.2) and 
drug release was observed in the formulation F4. Both polymers 
(HPMC E4M and Polyox WSR N60K) have shown a significant effect 
on lag period. As polymer concentration increase (level 1 to level 1) 
lag period was also get increased. The effect of the variables on the 
lag period in formulations F1–F9 are shown in Fig.4: 
Lag Period =+5.11+2.50𝐴𝐴+0.67𝐵𝐵–0.17𝐴𝐴𝐵𝐵---------------------------- (3) 
All the polynomial equations were found to be statistically 
significant (𝑃𝑃<0.01), as determined using ANOVA, as per the 
provision of Design Expert software. 
The combined effect of concentration of HPMC E4M and Polyox WSR 
N60K on lag period is shown in Fig.4. From response surface plot 
and contour plot in fig. 4, it was observed that both polymers have a 
significant effect on lag period. As concentration of HPMC E4M and 
Polyox WSRN60K increases (level+1, level+1) lag period is increased 
(>5 h) and uniformed[24]. At the maximum level of polymers, lag 
period was increased but did inhibit drug release. 
In vitro drug release 
From the fig. 5 and fig. 6, it was observed that 65 mg HPMC E4M 
(level 0) and 75 mg Polyox WSR N60K (level-1) in F4 batch have 
shown lag time of 4.20 h, followed by sigmoidal release pattern 
giving 100% drug release at 6th hour. As the concentration of the 
Polyox changes from F1 to F9 the lag time and drug release also 
changes at the 6th hour. 
Cumulative % Drug Release =+85.73–16.07𝐴𝐴 − 5.85𝐵𝐵 − 3.81𝐴𝐴𝐵𝐵-------
----------------- (4) 
where 𝐴𝐴 and 𝐵𝐵 represent the variables used in the formulations. All 
the polynomial equations were found to be statistically significant 
(𝑃𝑃<0.01), as determined using ANOVA, as per the provision of 
Design Expert software. The polynomial equations comprise the 
coefficients for intercept, first-order main effects, interaction terms, 
and higher order effects. The sign and magnitude of the main effects 
signify the relative influence of each factor on the response. The 
combined effect of concentration of HPMC E4M and Polyox WSR 
N60K on drug release was shown in fig. 5 and 6. As concentration of 
HPMC E4M and Polyox WSR N60K decreases (level −1, level −1) 
drug release is higher (>90%) and uniform [24, 25]. 
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Fig. 4: (a) Half-normal plot showing the influence on lag period, (b) Pareto chart, (c) Response surface plot, and (d) contour plot 
Malladi et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 5, 169-181 
 
178 
 
Fig. 5: In vitro drug release profiles of floating pulsatile release tablets of batches F1–F9. All values are represented as mean±SD (n=6) 
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Fig. 6: (a) Half-normal Plot showing the influence on cumulative % drug released at 6 h, (b) Pareto chart, (c) Response surface plot, and 
(d) contour plot 
 
FTIR study 
There was no interaction between the drug and polymers as showed 
in IR Graphs (fig. 7). IR spectrum of famotidine is characterized by 
the absorption of N-H group at 3400 cm−1. HPMC E4M has shown a 
major peak at 3443 and 2924. cm-1. Major peaks of the polymer are 
retained in spectra showing no chemical interaction between drug 
and polymer. In formulation due to cross-linking of polymers, few 
bands disappeared and merged.  
Whereas optimised formulation spectra shown 3401 cm-1 peaks 
indicating of pure drug and no change in the structure of the drug. 
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Fig. 7: FTIR graphs of famotidine, HPMC E4M, POLYOX N60K and optimised formulation Stability testing of the best formulation 
 
Optimised Formulation F4 was selected for the stability studies out 
of the total formulation batches. For condition 25 °C (±2 °C) and 
60% RH (±5%) and 40 °C (±2 °C) and 75% RH (±5%) was observed 
floating time (7.0–7.4±0.8 h) and assay (>97.35%) from initial to 3 
mo. From stability data, it can be concluded that there were no 
changes in any parameter tested in the formulation.  
CONCLUSION 
Floating pulsatile drug delivery system of famotidine was 
successfully developed using full factorial statistical design. The 
present research work demonstrates that famotidine could be 
successfully delivered to provide night-time relief of gastric acidity 
by formulating floating pulsatile drug delivery system. The dosage 
form needs to be taken after meal; where immediate release dose 
will provide relief from acid secretion in response to the meal, while 
programmed pulsatile release floating tablet with delayed “burst” 
release will reduce midnight acidity. This will provide an ideal 
therapeutic regimen with enhanced patient compliance. 
Concerning statistical analysis, it was shown that appropriate 
factorial design and optimization technique can be successfully used 
in the development of time-lagged press coating of formulations 
based on different levels of polymers to achieve the desired pulsed 
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release profile after a programmed lag time. Response surface 
methodology is an important tool for understanding the change of 
responses and locating the area of interest. The press-coated 
formulation containing HPMCE4M and Polyox WSR N60K at 0,-1 
level was in the optimum zone and has the potential for time-
controlled pulsatile delivery of Famotidine. The optimized 
formulation exhibited release profiles which were close to the 
predicted responses.  
Thus, the designed device can be considered as one of the promising 
formulation technique for preparing floating pulsatile drug delivery 
systems and hence in the chronotherapeutic management of 
nocturnal acid breakthrough by opening a “new therapeutic 
dimension” to an existing drug molecule. 
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